The first detailed study of the private tuberculosis (TB) drug market, published on May 4th, in the PLoS ONE journal, finds that the market is surprisingly large, and has irregular practices that could be driving treatment failures and contributing to the emergence of multidrug-resistant TB (MDR-TB).
Yesterday, Mario Raviglione , Director of Stop TB, and Giorgio Roscigno, CEO of FIND, held a global press conference announcing the World Health Organization’s endorsement of the new rapid diagnostic test Xpert MTB/RIF. If implemented to scale in countries where tuberculosis (TB) is endemic, it could revolutionize how TB is diagnosed and treated. The test could have a significant impact on patients that are smear negative, HIV positive, or infected with drug-resistant TB.
GlaxoSmithKline (GSK) researchers announced Wednesday that they have found a new compound that may help in the fight against drug-resistant bacteria. The findings could ultimately assist scientists in developing new antibiotics to tackle what has been called one of the world’s most pressing public health problems. Last year, a report from the American Academy of Microbiology called antibiotic resistance “an international pandemic,” adding that “resistance essentially is uncontrollable.”
Despite the massive need for new TB drugs, the commercial viability of the TB drug market has long been viewed as questionable at best. Reports suggest that there is a substantial market that will grow year-over-year, though there is no firm conclusion about its commercial viability. The first widely-circulated analysis was done by the Global [...]